Department of Pathology and Oncology, Juntendo University School of Medicine, Bunkyo, Tokyo 113-8421, Japan.
Oncol Rep. 2013 Apr;29(4):1492-500. doi: 10.3892/or.2013.2249. Epub 2013 Jan 24.
Chemoresistance is one of the main obstacles to successful cancer therapy and is frequently associated with multidrug resistance (MDR). One of the most studied mechanisms of MDR is the high expression of ATP-binding cassette (ABC) transporters. Here, we demonstrated that NP-1250, an ABCG2 inhibitor, induced apoptotic cell death in ABCG2-overexpressing multidrug-resistant MCF7/mitoxantrone-resistant (MX) human breast carcinoma cells via a caspase-independent pathway. Incubation of MCF7/MX cells with NP-1250 significantly reduced cell viability, while NP-1250 had little effect on the viability of drug-sensitive MCF7/wild-type cells. Although the target molecules of NP-1250 in cell death remain unknown, investigation of NP-1250 will aid in the elucidation of the molecular mechanism of drug resistance and NP-1250 may become a new therapy for MDR cancers.
耐药性是癌症治疗成功的主要障碍之一,通常与多药耐药性(MDR)有关。MDR 的最主要的机制之一是 ABC 转运蛋白的高表达。在这里,我们证明了 NP-1250,一种 ABCG2 抑制剂,通过 caspase 非依赖性途径诱导 ABCG2 过表达的多药耐药 MCF7/米托蒽醌耐药(MX)人乳腺癌细胞发生凋亡性细胞死亡。NP-1250 孵育 MCF7/MX 细胞可显著降低细胞活力,而 NP-1250 对药物敏感的 MCF7/野生型细胞的活力几乎没有影响。虽然 NP-1250 在细胞死亡中的靶分子尚不清楚,但对 NP-1250 的研究将有助于阐明耐药性的分子机制,NP-1250 可能成为治疗多药耐药性癌症的一种新疗法。